Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The inducible caspase 9 (iCasp9) suicide switch is a genetically engineered safety mechanism designed to selectively induce apoptosis in modified cells, such as T cells used in adoptive cell therapies. This system provides a rapid and controllable way to eliminate therapeutic cells if severe adverse effects or off-target toxicities occur, thereby improving the safety profile of cellular immunotherapies. It consists of the intracellular domain of human caspase-9 fused to a modified drug-binding domain from human FKBP12. Activation requires a small-molecule CID like AP1903/Rimiducid, which dimerizes iCasp9, triggering apoptosis.
Dimerization and activation of caspase-9, leading to downstream activation of effector caspases and apoptosis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inducible Caspase 9 Suicide Switch (iCasp9).